Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 58 articles:
HTML format

Single Articles

    July 2022
  1. TISSEVERASINGHE S, Tolba M, Saad F, Gravis G, et al
    Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?
    J Clin Oncol. 2022 Jul 21:JCO2200883. doi: 10.1200/JCO.22.00883.

    June 2022
  2. JACKSON WC, Tang M, Schipper MJ, Sandler HM, et al
    Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
    J Clin Oncol. 2022 Jun 23:JCO2102741. doi: 10.1200/JCO.21.02741.
    PubMed     Abstract available

  3. KARTOLO A, Tannock IF, Vera Badillo FE
    Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    J Clin Oncol. 2022 Jun 20:JCO2200705. doi: 10.1200/JCO.22.00705.

  4. MADAN RA, Mena E, Lindenberg L, Choyke PL, et al
    With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.
    J Clin Oncol. 2022 Jun 3:JCO2200493. doi: 10.1200/JCO.22.00493.

  5. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    PubMed     Abstract available

    May 2022
  6. CAO Y, Deville C Jr
    Adjuvant Radiation for Pathologically Node-Positive Prostate Cancer: Evidence When Early Salvage May Not Be Early Enough.
    J Clin Oncol. 2022 May 23:JCO2200645. doi: 10.1200/JCO.22.00645.

    April 2022
  7. AGARWAL N, Tangen CM, Hussain MHA, Gupta S, et al
    Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
    J Clin Oncol. 2022 Apr 21:JCO2102517. doi: 10.1200/JCO.21.02517.
    PubMed     Abstract available

  8. HUSSAIN M, Carducci MA, Clarke N, Fenton SE, et al
    Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
    J Clin Oncol. 2022 Apr 19:JCO2200208. doi: 10.1200/JCO.22.00208.

  9. EGGENER SE, Berlin A, Vickers AJ, Paner GP, et al
    Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.
    J Clin Oncol. 2022 Apr 18:JCO2200123. doi: 10.1200/JCO.22.00123.

  10. ARMSTRONG AJ, Azad AA, Iguchi T, Szmulewitz RZ, et al
    Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2022 Apr 14:JCO2200193. doi: 10.1200/JCO.22.00193.
    PubMed     Abstract available

    March 2022
  11. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2022 Mar 15:JCO2102800. doi: 10.1200/JCO.21.02800.
    PubMed     Abstract available

    February 2022
  12. PATEL NA, Reiter RE
    Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer.
    J Clin Oncol. 2022 Feb 24:JCO2102940. doi: 10.1200/JCO.21.02940.

  13. VAN WAMBEKE S, Vera-Badillo FE, Gyawali B
    Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?
    J Clin Oncol. 2022 Feb 21:JCO2102304. doi: 10.1200/JCO.21.02304.

    January 2022
  14. SCHODER H, Hope TA, Knopp M, Kelly WK, et al
    Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.
    J Clin Oncol. 2022 Jan 11:JCO2102440. doi: 10.1200/JCO.21.02440.
    PubMed     Abstract available

  15. MORGANS AK, Beltran H
    Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer.
    J Clin Oncol. 2022 Jan 6:JCO2102530. doi: 10.1200/JCO.21.02530.
    PubMed     Abstract available

  16. DZIMITROWICZ HE, Armstrong AJ
    Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.
    J Clin Oncol. 2022 Jan 6:JCO2102504. doi: 10.1200/JCO.21.02504.

    December 2021
  17. STOCKLER MR, Martin AJ, Davis ID, Dhillon HM, et al
    Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
    J Clin Oncol. 2021 Dec 20:JCO2100941. doi: 10.1200/JCO.21.00941.
    PubMed     Abstract available

    November 2021
  18. RUSH HL, Murphy L, Morgans AK, Clarke NW, et al
    Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
    J Clin Oncol. 2021 Nov 10:JCO2100728. doi: 10.1200/JCO.21.00728.
    PubMed     Abstract available

  19. SADA YH
    A Dozen Eggs.
    J Clin Oncol. 2021;39:3645-3646.

    September 2021
  20. KERKMEIJER LGW, Pos FJ, Haustermans K, van der Heide UA, et al
    Reply to I. R. Vogelius et al.
    J Clin Oncol. 2021;39:3086-3087.

    July 2021
  21. BOLLA M, Neven A, Maingon P, Carrie C, et al
    Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
    J Clin Oncol. 2021 Jul 26:JCO2100855. doi: 10.1200/JCO.21.00855.
    PubMed     Abstract available

  22. SPERGER JM, Emamekhoo H, McKay RR, Stahlfeld CN, et al
    Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
    J Clin Oncol. 2021 Jul 1:JCO2100169. doi: 10.1200/JCO.21.00169.
    PubMed     Abstract available

  23. D'AMICO AV, Xie W, McMahon E, Loffredo M, et al
    Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
    J Clin Oncol. 2021 Jul 1:JCO2100596. doi: 10.1200/JCO.21.00596.
    PubMed     Abstract available

    June 2021
  24. VOGELIUS IR, Bentzen SM
    Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?
    J Clin Oncol. 2021 Jun 4:JCO2100586. doi: 10.1200/JCO.21.00586.

  25. YANG DD, Nguyen PL, D'Amico AV
    Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited.
    J Clin Oncol. 2021 Jun 4:JCO2100621. doi: 10.1200/JCO.21.00621.

  26. BRENNEMAN RJ, Baumann BC, Gay HA, Michalski JM, et al
    Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer.
    J Clin Oncol. 2021 Jun 4:JCO2100634. doi: 10.1200/JCO.21.00634.

  27. DESS RT, Jackson WC, Spratt DE
    End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?
    J Clin Oncol. 2021 Jun 4:JCO2100376. doi: 10.1200/JCO.21.00376.

  28. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2021 Jun 4:JCO2003714. doi: 10.1200/JCO.20.03714.
    PubMed     Abstract available

    May 2021
  29. TEWARI AK, Gillessen S, Sweeney CJ
    Metastatic Prostate Cancer: In Search of More Granularity.
    J Clin Oncol. 2021 May 14:JCO2100643. doi: 10.1200/JCO.21.00643.

    April 2021
  30. HOCHT S, Mason M, Wiegel T
    Timing of ADT in Radiotherapy of Prostate Cancer.
    J Clin Oncol. 2021 Apr 29:JCO2100032. doi: 10.1200/JCO.21.00032.

  31. CHI KN, Chowdhury S, Bjartell A, Chung BH, et al
    Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    J Clin Oncol. 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
    PubMed     Abstract available

  32. MURPHY AB, Abern MR, Liu L, Wang H, et al
    Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.
    J Clin Oncol. 2021 Apr 9:JCO2002997. doi: 10.1200/JCO.20.02997.
    PubMed     Abstract available

    March 2021
  33. JAN I, Parikh RR
    Feeding the Controversy: When Pelvic Irradiation Improves Outcomes in High-Risk and Very High-Risk Prostate Cancer.
    J Clin Oncol. 2021 Mar 8:JCO2003636. doi: 10.1200/JCO.20.03636.
    PubMed     Abstract available

    February 2021
  34. DENMEADE SR, Wang H, Agarwal N, Smith DC, et al
    TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
    J Clin Oncol. 2021 Feb 22:JCO2002759. doi: 10.1200/JCO.20.02759.
    PubMed     Abstract available

    January 2021
  35. MURTHY V, Maitre P, Kannan S, Panigrahi G, et al
    Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.
    J Clin Oncol. 2021 Jan 26:JCO2003282. doi: 10.1200/JCO.20.03282.
    PubMed     Abstract available

  36. VIRGO KS, Rumble RB, de Wit R, Mendelson DS, et al
    Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
    J Clin Oncol. 2021 Jan 26:JCO2003256. doi: 10.1200/JCO.20.03256.
    PubMed     Abstract available

  37. KERKMEIJER LGW, Groen VH, Pos FJ, Haustermans K, et al
    Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
    J Clin Oncol. 2021 Jan 20:JCO2002873. doi: 10.1200/JCO.20.02873.
    PubMed     Abstract available

  38. SPRATT DE, Malone S, Roy S, Grimes S, et al
    Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
    J Clin Oncol. 2021;39:136-144.
    PubMed     Abstract available

    December 2020
  39. CRABB SJ, Griffiths G, Marwood E, Dunkley D, et al
    Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
    J Clin Oncol. 2020 Dec 16:JCO2001576. doi: 10.1200/JCO.20.01576.
    PubMed     Abstract available

    November 2020
  40. JACKSON WC, Hartman HE, Dess RT, Spratt DE, et al
    Reply to L. C. Mendez et al and M. A. Kollmeier et al.
    J Clin Oncol. 2020;38:3823-3824.

  41. KOLLMEIER MA, McBride S, Gorovets D, Zelefsky MJ, et al
    Role of Androgen-Deprivation Therapy Remains Uncertain for Intermediate-Risk Patients When Using Dose-Escalated Radiotherapy.
    J Clin Oncol. 2020;38:3821-3822.

    October 2020
  42. HUSSAIN M, Lin D, Saad F, Vapiwala N, et al
    Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
    J Clin Oncol. 2020 Oct 13:JCO2002268. doi: 10.1200/JCO.20.02268.

  43. DALLA VOLTA A, Mazziotti G, Maffezzoni F, Grisanti S, et al
    Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
    J Clin Oncol. 2020;38:3363-3366.

    September 2020
  44. CASTRO MENDEZ L, Martell K, Crook JM
    Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision.
    J Clin Oncol. 2020 Sep 30:JCO2001566. doi: 10.1200/JCO.20.01566.

  45. KYRIAKOPOULOS CE, Heath EI, Ferrari A, Sperger JM, et al
    Exploring Spatial-Temporal Changes in (18)F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide.
    J Clin Oncol. 2020 Sep 8:JCO2000348. doi: 10.1200/JCO.20.00348.
    PubMed     Abstract available

  46. SCHWEIZER MT, Cheng HH, Nelson PS, Montgomery RB, et al
    Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
    J Clin Oncol. 2020 Sep 8:JCO2001755. doi: 10.1200/JCO.20.01755.

  47. MARKOWSKI MC, Antonarakis ES
    BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
    J Clin Oncol. 2020 Sep 1:JCO2002246. doi: 10.1200/JCO.20.02246.

    August 2020
  48. ABIDA W, Patnaik A, Campbell D, Shapiro J, et al
    Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
    J Clin Oncol. 2020 Aug 14:JCO2001035. doi: 10.1200/JCO.20.01035.
    PubMed     Abstract available

    July 2020
  49. EASTHAM JA, Heller G, Halabi S, Monk JP 3rd, et al
    Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
    J Clin Oncol. 2020 Jul 24:JCO2000315. doi: 10.1200/JCO.20.00315.
    PubMed     Abstract available

    June 2020
  50. XIE W, Regan MM, Buyse M, Halabi S, et al
    Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
    J Clin Oncol. 2020 Jun 18:JCO1903114. doi: 10.1200/JCO.19.03114.
    PubMed     Abstract available

  51. GIRI VN, Knudsen KE, Kelly WK, Cheng HH, et al
    Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    J Clin Oncol. 2020 Jun 9:JCO2000046. doi: 10.1200/JCO.20.00046.
    PubMed     Abstract available

    May 2020
  52. ROY S, Malone S
    Reply to P. Ghadjar et al.
    J Clin Oncol. 2020;38:1747-1748.

  53. JACKSON WC, Hartman HE, Dess RT, Birer SR, et al
    Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
    J Clin Oncol. 2020 May 12:JCO1903217. doi: 10.1200/JCO.19.03217.
    PubMed     Abstract available

  54. LIN DW, Zheng Y, McKenney JK, Brown MD, et al
    17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort.
    J Clin Oncol. 2020;38:1549-1557.
    PubMed     Abstract available

  55. MARSHALL CH, Joshu CE
    Mounting Weight of Evidence on the Importance of Body Weight for Men With Prostate Cancer.
    J Clin Oncol. 2020 May 5:JCO2000791. doi: 10.1200/JCO.20.00791.

    April 2020
  56. TROESCHEL AN, Hartman TJ, Jacobs EJ, Stevens VL, et al
    Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.
    J Clin Oncol. 2020 Apr 6:JCO1902185. doi: 10.1200/JCO.19.02185.
    PubMed     Abstract available

    February 2020
  57. AGOCHUKWU NQ, Wittmann D, Boileau NR, Dunn RL, et al
    Reply to K.P. Weinfurt et al.
    J Clin Oncol. 2020;38:654-655.

    Reply to K.P. Weinfurt et al.
    J Clin Oncol. 2020;38:653-654.

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.